Current and Evolving Management of Chronic Hepatitis Delta Virus (HDV) Infection

被引：0

作者：

Anolli, Maria Paola ^{[1
]}

Degasperi, Elisabetta ^{[1
]}

Lampertico, Pietro ^{[1
,2
]}

机构：

[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Via F Sforza 35, I-20122 Milan, Italy

[2] Univ Milan, CRC AM & A Migliavacca Ctr Liver Dis, Dept Pathophysiol & Transplantat, Milan, Italy

来源：

CURRENT HEPATOLOGY REPORTS | 2023年 / 22卷 / 03期

关键词：

Hepatitis; Delta; Bulevirtide; Lonafarnib; HDV RNA; Cirrhosis; MG DOSE LEVEL; 3; CLINICAL-TRIALS; BULEVIRTIDE MONOTHERAPY; PEGINTERFERON ALPHA-2A; COMPENSATED CIRRHOSIS; TENOFOVIR DISOPROXIL; LAMBDA MONOTHERAPY; 24-WEEK DATA; EFFICACY; SAFETY;

D O I：

10.1007/s11901-023-00606-7

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Purpose of ReviewThis review aims to examine the current and evolving management of chronic hepatitis delta virus (HDV) infection, a severe form of viral hepatitis characterized by accelerated liver disease progression, leading to cirrhosis and its complications. Previously, off-label interferon (IFN) administration was the only treatment option for HDV infection, with limited effectiveness and several side effects.Recent FindingsThe discovery of the entry inhibitor bulevirtide (BLV) has been a breakthrough in HDV treatment, showing high rates of viral suppression in clinical trials and in real-life studies. Other compounds, such as lonafarnib and new anti-HBV drugs, are under development to provide alternative or combined treatment strategies.SummarySince HDV's discovery, more than 40 years ago, the current treatment scenario for HDV is rapidly evolving: while BLV is the first approved drug for HDV treatment, with proven effectiveness also in real-life settings, many other compounds are currently under investigation.

引用

页码：138 / 146

页数：9

共 50 条

[1]

Agarwal K, Late Breaking Abstracts of the 2022 AASLD Liver

[2]

Allweiss L, 2021, HEPATOLOGY, V74, p148A

[3] Extension of Bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the italian multicenter study (HEP4Di) [J].

Anolli, M. P. ;

Degasperi, E. ;

D'Offizi, G. ;

Brunetto, M. R. ;

Verucchi, G. ;

Federico, A. ;

Ciancio, A. ;

Mangia, A. ;

Santantonio, T. A. ;

Coppola, N. ;

Pellicelli, A. ;

Loglio, A. ;

Vigano, M. ;

Pileri, F. ;

Maracci, Monia ;

Puoti, M. ;

Piscaglia, F. ;

Lampertico, P. .

DIGESTIVE AND LIVER DISEASE, 2023, 55 :S7-S7

[4] A 3-year course of bulevirtide monotherapy may cure HDV infection in patients with cirrhosis [J].

Anolli, Maria Paola ;

Degasperi, Elisabetta ;

Allweiss, Lena ;

Sangiovanni, Angelo ;

Maggioni, Marco ;

Scholtes, Caroline ;

Oberhardt, Valerie ;

Neumann-Haefelin, Christoph ;

Dandri, Maura ;

Zoulim, Fabien ;

Lampertico, Pietro .

JOURNAL OF HEPATOLOGY, 2023, 78 (04) :876-880

[5]

Anolli MP, 2023, Liver Int

[6]

Asselah T, 2021, J HEPATOL, V75, pS291

[7] Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naive to Nucleos(t)ide Therapy [J].

Bazinet, Michel ;

Pantea, Victor ;

Placinta, Gheorghe ;

Moscalu, Iurie ;

Cebotarescu, Valentin ;

Cojuhari, Lilia ;

Jimbei, Pavlina ;

Iarovoi, Liviu ;

Smesnoi, Valentina ;

Musteata, Tatiana ;

Jucov, Alina ;

Dittmer, Ulf ;

Krawczyk, Adalbert ;

Vaillant, Andrew .

GASTROENTEROLOGY, 2020, 158 (08) :2180-2194

[8] Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection [J].

Brancaccio, Giuseppina ;

Gaeta, Giovanni B. .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 54 (06) :697-701

[9] Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation [J].

Bremer, Birgit ;

Anastasiou, Olympia E. ;

Ciesek, Sandra ;

Weelemeyer, Heiner .

ANTIVIRAL THERAPY, 2019, 24 (02) :117-123

[10]

Buti M, 2022, HEPATOLOGY, V76, pS224

← 1 2 3 4 5 →